 <h1>Dalbavancin Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to dalbavancin: intravenous powder for solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, dalbavancin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking dalbavancin:</p><p>
<i>Less common or rare</i>
</p><ul>
<li>Abdominal or stomach pain or tenderness</li>
<li>back pain</li>
<li>black, tarry stools</li>
<li>bleeding gums</li>
<li>blood in the urine or stools</li>
<li>chest pain or tightness</li>
<li>chills</li>
<li>clay colored stools</li>
<li>cough</li>
<li>dark urine</li>
<li>decreased appetite</li>
<li>difficulty swallowing</li>
<li>dizziness</li>
<li>fast heartbeat</li>
<li>feeling of warmth</li>
<li>fever</li>
<li>headache</li>
<li>hives, welts, itching, or rash</li>
<li>loss of appetite</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>pinpoint red spots on the skin</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>redness of the face, neck, arms, and occasionally, upper chest</li>
<li>redness of the skin</li>
<li>severe abdominal or stomach cramps and pain</li>
<li>sore mouth or tongue</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>swelling of the feet or lower legs</li>
<li>swollen glands</li>
<li>tightness in the chest</li>
<li>troubled breathing with exertion</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>vomiting of blood or material that looks like coffee grounds</li>
<li>watery and severe diarrhea, which may also be bloody</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of dalbavancin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Diarrhea</li>
</ul><p>
<i>Less common or rare</i>
</p><ul>
<li>Anxiety</li>
<li>blurred vision</li>
<li>cold sweats</li>
<li>coma</li>
<li>confusion</li>
<li>cool, pale skin</li>
<li>depression</li>
<li>increased hunger</li>
<li>nightmares</li>
<li>seizures</li>
<li>shakiness</li>
<li>slurred speech</li>
</ul><p>
<!-- end intravenous powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to dalbavancin: intravenous powder for injection</i></p><h3>General</h3><p>The most common adverse reactions were nausea, headache, and diarrhea.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Frequency not reported</b>: Anemia, hemorrhagic anemia, leucopenia, neutropenia, thrombocytopenia, petechiae, eosinophilia, thrombocytosis, international normalized ratio increased, phlebitis, wound hemorrhage, spontaneous hematoma<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash, pruritus</p>
<p><b>Frequency not reported</b>: Urticaria, flushing<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, diarrhea, vomiting</p>
<p><b>Frequency not reported</b>: Gastrointestinal hemorrhage, melena, hematochezia, abdominal pain<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Frequency not reported</b>: Hepatotoxicity, hepatic transaminases increased, blood alkaline phosphatase increased<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Anaphylactoid reaction<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Clostridium difficile colitis, oral candidiasis, vulvovaginal mycotic infection<sup>[Ref]</sup></p><h3>Local</h3><p><b>Frequency not reported</b>: Infusion-related reactions<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Hypoglycemia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache</p>
<p><b>Frequency not reported</b>: Dizziness<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Frequency not reported</b>: Bronchospasm<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc., Chicago, IL. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about dalbavancin</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>1 Review</li>
<li>Drug class: glycopeptide antibiotics</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Dalbavancin Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Dalvance</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Skin and Structure Infection</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to dalbavancin: intravenous powder for injection</i></p><h3>General</h3><p>The most common adverse reactions were nausea, headache, and diarrhea.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Frequency not reported</b>: Anemia, hemorrhagic anemia, leucopenia, neutropenia, thrombocytopenia, petechiae, eosinophilia, thrombocytosis, international normalized ratio increased, phlebitis, wound hemorrhage, spontaneous hematoma<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash, pruritus</p><p><b>Frequency not reported</b>: Urticaria, flushing<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, diarrhea, vomiting</p><p><b>Frequency not reported</b>: Gastrointestinal hemorrhage, melena, hematochezia, abdominal pain<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Frequency not reported</b>: Hepatotoxicity, hepatic transaminases increased, blood alkaline phosphatase increased<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Anaphylactoid reaction<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Clostridium difficile colitis, oral candidiasis, vulvovaginal mycotic infection<sup>[Ref]</sup></p><h3>Local</h3><p><b>Frequency not reported</b>: Infusion-related reactions<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Hypoglycemia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache</p><p><b>Frequency not reported</b>: Dizziness<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Frequency not reported</b>: Bronchospasm<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc., Chicago, IL. </p><h2>More about dalbavancin</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>1 Review</li>
<li>Drug class: glycopeptide antibiotics</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Dalbavancin Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Skin and Structure Infection</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>